Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news
Mayo Clinic Q and A: Congestive heart failure and diet
DEAR MAYO CLINIC: My doctor told me that I have congestive heart failure and I have to change my lifestyle, including my diet. What kind of diet should I be on? ANSWER: When patients have congestive heart failure, their heart isn't able to manage fluid well, and it builds up in the body. This fluid can cause shortness [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2021 Category: Databases & Libraries Source Type: news
Increased risk of congestive heart failure following carbon monoxide poisoning - Huang CC, Chen TH, Ho CH, Chen YC, Hsu CC, Lin HJ, Wang JJ, Chang CP, Guo HR.
BACKGROUND: Carbon monoxide poisoning (COP) is an important public health issue around the world. It may increase the risk of myocardial injury, but the association between COP and congestive heart failure (CHF) remains unclear. We conducted a study incorp... (Source: SafetyLit)
Source: SafetyLit - April 23, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Amid COVID, potentially avoidable hospitalizations for other conditions fell far more for whites than Blacks
During the first six months of the pandemic, as people attempted to stay away from hospitals caring for those sick with COVID-19, potentially avoidable hospitalizations for non-COVID-19 –related conditions fell far more among white patients than Black patients, according to a new study that looked at admissions to UCLA Health hospitals.The findings indicate that the COVID-19 crisis has exacerbated existing racial health care disparities and suggest that during the pandemic, African Americans may have had worse access than whites to outpatient care that could have helped prevent deterioration of their non –COVID-19 heal...
Source: UCLA Newsroom: Health Sciences - March 19, 2021 Category: Universities & Medical Training Source Type: news
Radiological Case: Barth Syndrome: A Rare Cause of CHF in Boys Radiological Case: Barth Syndrome: A Rare Cause of CHF in Boys
Review the radiological findings and differential diagnosis of Barth syndrome, a rare X-linked recessive disorder which causes congestive heart failure in young males.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 9, 2021 Category: Radiology Tags: Radiology Journal Article Source Type: news
Stomach bloating warning: A bloated tummy could mean your heart is struggling
STOMACH bloating may be a warning sign of congestive heart failure - when the muscle is unable to effectively pump blood around the body. The progressive condition will eventually be fatal, which is why an early diagnosis might help prolong life. (Source: Daily Express - Health)
Source: Daily Express - Health - March 4, 2021 Category: Consumer Health News Source Type: news
Mayo Clinic Q & amp;A podcast: Symptoms for cardiac amyloidosis overlap with other conditions
Cardiac amyloidosis is irreversible thickening of the heart muscle that typically presents as a form of congestive heart failure. It is overlooked often because the symptoms can masquerade as other conditions. Unfortunately, there aren't any preventive strategies for cardiac amyloidosis, says Dr. Melissa Lyle, a Mayo Clinic cardiologist. "So the key, really, is early detection," says [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 19, 2021 Category: Databases & Libraries Source Type: news
Do patients manage their health care better if they can access their electronic health records?
What are electronic health records?Healthcare providers maintain health-related information about a patient in an electronic health record, which is held in a digitalform and is accessed by a computer. Healthcare professionals use these records to access all health-related information for a patient ' scare, whenever and wherever they need it. Information may include a person ' s medical history, medicines, allergies, test results, andimmunisation history.Some healthcare providers let patients see their own electronic health records, usually by giving them web-based access. Patients may alsobe oDered other web-based service...
Source: Cochrane News and Events - February 16, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Higher blood pressure over life span increases congestive heart failure risk in Black people
(Medical College of Georgia at Augusta University) Starting with early childhood, otherwise healthy Black people show signs of slightly diminished heart muscle strength and a slightly higher blood pressure than their white counterparts, factors which may put them on a course for early development of congestive heart failure, Medical College of Georgia researchers report. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2021 Category: International Medicine & Public Health Source Type: news
Stomach bloating: Coughing up pink, frothy fluid is a sign of congestive heart failure
STOMACH bloating may be a warning sign your heart is failing. This means the muscle isn't able to pump blood around the body as well as it should. Congestive heart failure can develop slowly over years or can be sudden. (Source: Daily Express - Health)
Source: Daily Express - Health - February 6, 2021 Category: Consumer Health News Source Type: news
What Are the 4 Stages of Congestive Heart Failure
What Are the Four Stages of Congestive Heart Failure? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
